Company Research Report: PsychoGenics Inc.

Company Overview

Name:

PsychoGenics Inc.

Mission of the Company:

PsychoGenics' mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next breakthroughs for severely disabling CNS and orphan disorders, and reduce the attrition rate in clinical development.

Founding Year and Founders:

No information is available.

Key People in the Company:

Emer Leahy, Ph.D., MBA: President and CEO

David Bleakman, Ph.D.: President, Drug Discovery and Development

Mark Varney, Ph.D.: Chief Scientific Officer

Dani Brunner, Ph.D.: Chief Innovation Officer, Chief Technology Officer

Taleen Hanania, Ph.D.: Chief Commercial Officer

Sylvie Ramboz, Ph.D.: Sr. VP, Behavioral Pharmacology

Afshin Ghavami, Ph.D.: VP, Research Operations

Stephen Morairty, Ph.D.: VP, Translational Neuroscience

Leslie Street, Ph.D.: VP, Medicinal Chemistry

Christina Leahy: Sr. VP, QA and Regulatory Affairs

Ronald E.D. Christopher: VP, Finance

Kathleen Kelly: VP, Human Resources

Headquarters:

215 College Road, Paramus, NJ 07652

Number of Employees:

No information is available.

Revenue of the Company:

No information is available.

What the Company is Known For:

PsychoGenics is known for its high-quality, cutting-edge translational approach to research and customized solutions to support clients quantify the efficacy of their treatments before clinical trials.

Products and Services

Key Products and Services:

Behavioral Testing: Comprehensive in vivo testing capabilities.

Electrophysiology: State-of-the-art technologies for detailed analysis.

Translational EEG: Advanced techniques for neurological assessment.

Quantitative Histology: Precise and detailed tissue analysis.

Molecular Biology: Innovative molecular testing and analysis.

Microdialysis: Techniques for measuring neurotransmitter dynamics.

Pharmacokinetic/Bioanalysis: In-depth bioanalytical services.

Drug Abuse Liability: Testing for potential drug abuse risks.

Receptor Occupancy: Analysis measuring drug-receptor interactions.

High-Level Descriptions and Key Features:

1. Behavioral and In Vivo Testing:

In-depth behavioral assays.

Validated disease models for multiple CNS disorders.

2. Electrophysiology:

Detailed neuronal activity measurement.

Supports several research areas including neurodegenerative disorders.

3. Translational EEG:

Advanced EEG techniques.

Essential for translational research.

4. Histology & IHC:

Precision tissue analysis.

Provides insights on cellular and molecular level changes.

5. Molecular Biology:

Advanced diagnostic tools.

Encompasses a variety of CNS and rare disorder studies.

6. Microdialysis:

Measuring realtime in vivo neurotransmitter levels.

Crucial for pharmacodynamic studies.

7. Pharmacokinetic/Bioanalysis:

Comprehensive drug metabolism analysis.

Supports various stages of drug discovery and development.

8. Receptor Occupancy:

Quantitative analysis of drug binding.

Essential for analyzing drug efficacy and pharmacodynamics.

Cube Technologies:

Cube Technologies revolutionizes neuropsychiatric drug discovery by utilizing an AI-enabled platform to accelerate the identification of promising drug candidates.

Recent Developments

New Products Launched:

No information is available.

New Features Added to Existing Products:

No information is available.

Recent Developments and Partnerships:

PsychoGenics was awarded a $3 million SBIR Grant to employ its AI-enabled platforms to find treatments for rare disorders (August 28, 2024).

Industry news includes advancements in AI-enabled polypharmacology and significant research grants from agencies such as the Christopher and Dana Reeve Foundation.